Published in Psychiatry (Edgmont) on March 01, 2007
Vocal acoustic biomarkers of depression severity and treatment response. Biol Psychiatry (2012) 0.89
The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports. Drug Healthc Patient Saf (2013) 0.77
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Capturing the patient's view of change as a clinical outcome measure. JAMA (1999) 4.11
Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol (2002) 3.58
Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry (2002) 3.47
Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res (2002) 1.78
The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res (2000) 1.64
Patient and rater education of expectations in clinical trials (PREECT). J Clin Psychopharmacol (2001) 1.56
Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. Neuropsychopharmacology (2005) 1.47
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol (2004) 1.40
Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry (2006) 0.90
Factors contributing to failed trials of new agents: can technology prevent some problems? J Clin Psychiatry (2002) 0.89
The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry (2002) 6.02
Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial. Psychother Psychosom (2002) 1.94
Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology. J Psychiatr Res (2010) 1.43
Assessing the onset of antidepressant-induced sexual dysfunction using interactive voice response technology. J Clin Psychiatry (2007) 1.06
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin (2007) 1.04
Prediction of suicidal behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry (2013) 1.01
A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode. Int Clin Psychopharmacol (2012) 0.94
Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol (2007) 0.94
Validation of an IVRS version of the MADRS. J Psychiatr Res (2005) 0.92
Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephones. Alzheimer Dis Assoc Disord (2007) 0.91
An examination of 26,168 Hamilton Depression Rating Scale scores administered via interactive voice response across 17 randomized clinical trials. J Clin Psychopharmacol (2006) 0.90
A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology. J Clin Psychiatry (2007) 0.89
The effect of dermatologic precautions on the incidence of rash with addition of lamotrigine in the treatment of bipolar I disorder: a randomized trial. J Clin Psychiatry (2006) 0.89
A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. J Clin Psychiatry (2007) 0.86
A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry (2003) 0.83
St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol (2005) 0.82
A novel interactive voice response (IVR) system for dementia screening, education, and referral: one-year summary. Alzheimer Dis Assoc Disord (2005) 0.81
WCA recommendations for the long-term treatment of panic disorder. CNS Spectr (2003) 0.80
Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine. Psychiatry (Edgmont) (2007) 0.79
Cost-effectiveness of computer-aided behaviour therapy for obsessive-compulsive disorder. Psychother Psychosom (2007) 0.79
Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol (2002) 0.79
A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. J Clin Psychiatry (2008) 0.78
Voice response system to measure healthcare costs: a STAR*D report. Am J Manag Care (2009) 0.78
Duloxetine in practice-based clinical settings: assessing effects on the emotional and physical symptoms of depression in an open-label, multicenter study. Prim Care Companion J Clin Psychiatry (2007) 0.75
Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies. Int Clin Psychopharmacol (2013) 0.75
Assessing onset of treatment benefit in depression and anxiety: conceptual considerations. J Clin Psychiatry (2009) 0.75
Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry (2006) 0.75
WCA recommendations for the long-term treatment of social phobia. CNS Spectr (2003) 0.75